Enhancement of α-Helicity in the HIV-1 Inhibitory Peptide DP178 Leads to an Increased Affinity for Human Monoclonal Antibody 2F5 but Does Not Elicit Neutralizing Responses in Vitro-Reference-Cited by-同舟云学术

Enhancement of α-Helicity in the HIV-1 Inhibitory Peptide DP178 Leads to an Increased Affinity for Human Monoclonal Antibody 2F5 but Does Not Elicit Neutralizing Responses in Vitro

Published:2002-11 Issue:48 Volume:277 Page:45811-45820
ISSN:0021-9258
Container-title:Journal of Biological Chemistry
language:en
Short-container-title:Journal of Biological Chemistry

Author:

Joyce Joseph G.,Hurni William M.,Bogusky Michael J.,Garsky Victor M.,Liang Xiaoping,Citron Michael P.,Danzeisen Renee C.,Miller Michael D.,Shiver John W.,Keller Paul M.

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry

Reference60 articles.

1. Maturation of HIV envelope glycoprotein precursors by cellular endoproteases

2. HIV Entry and Its Inhibition

3. HIV-1 Entry Inhibitors in the Side Pocket

4. Neutralization of HIV-1 by antibody

5. Immunogenicity and Protective Efficacy of Oligomeric Human Immunodeficiency Virus Type 1 gp140

Cited by 112 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stabilized trimeric peptide immunogens of the complete HIV-1 gp41 N-heptad repeat and their use as HIV-1 vaccine candidates;Proceedings of the National Academy of Sciences;2024-05-20

2. Characterizing Native and Hydrocarbon-Stapled Enfuvirtide Conformations with Ion Mobility Mass Spectrometry and Hydrogen–Deuterium Exchange;Journal of the American Society for Mass Spectrometry;2021-02-03

3. Peptide-Based Vaccination for Antibody Responses Against HIV;Vaccines;2019-09-02

4. An Outdated Notion of Antibody Specificity Is One of the Major Detrimental Assumptions of the Structure-Based Reverse Vaccinology Paradigm, Which Prevented It from Helping to Develop an Effective HIV-1 Vaccine;HIV/AIDS: Immunochemistry, Reductionism and Vaccine Design;2019

5. Requirements for Empirical Immunogenicity Trials, Rather than Structure-Based Design, for Developing an Effective HIV Vaccine;HIV/AIDS: Immunochemistry, Reductionism and Vaccine Design;2019